• Incruse®▼ Ellipta® 55 micrograms (umeclidinium bromide) manufactured by GSK is a dry powder for inhalation which was launched in the UK in July 2014. UKMI has assessed this new product using the UKMI product safety tool.
  • The product is indicated for maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). It one of three Ellipta® inhalers available the UK.
    Other Ellipta® products are:
  • Relvar®▼ containing vilanterol trifenetate and fluticasone (note: two strengths are available; the 99/22 microgram strength is licensed for COPD and asthma and the 184/22 microgram strength is licensed for asthma only).
  • Anoro®▼containing vilanterol trifenatate and umeclidinium bromide

NOTE: The content of this resource has not been updated since the publication date. Some information may be out of date and links to other documents or website may not work.

Attachments